Category: 1023595-19-8

A catalyst don’t appear in the overall stoichiometry of the reaction it catalyzes, HPLC of Formula: C14H26N2O2, but it must appear in at least one of the elementary reactions in the mechanism for the catalyzed reaction. 1023595-19-8, Name is 9-Boc-2,9-diazaspiro[5.5]undecane, molecular formula is C14H26N2O2. In a Patent, authors is ，once mentioned of 1023595-19-8

There is provided compounds of formula (I), wherein R1, R2, X, R3 and R4 have meanings given in the description (and which compounds are optionally substituted as indicated in the description), and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. a PIM family kinase, such as PIM-1, PIM-2 and/or PIM-3) is desired and/or required, and particularly in the treatment of cancer or a proliferative disease. There is also provided combinations comprising the compounds of formula (I).

I hope this article can help some friends in scientific research. I am very proud of our efforts over the past few months and hope to 1023595-19-8, help many people in the next few years.HPLC of Formula: C14H26N2O2

Reference：
Piperidine – Wikipedia,
Piperidine | C5H20917N – PubChem

Chemistry is the experimental and theoretical study of materials on their properties at both the macroscopic and microscopic levels.In a patent， Computed Properties of C14H26N2O2, Which mentioned a new discovery about 1023595-19-8

With the success of protein kinase inhibitors as drugs to target cancer, there is a continued need for new kinase inhibitor scaffolds. We have investigated the synthesis and kinase inhibition of new heteroaryl-substituted diazaspirocyclic compounds that mimic ATP. Versatile syntheses of substituted diazaspirocycles through ring-closing metathesis were demonstrated. Diazaspirocycles directly linked to heteroaromatic hinge binder groups provided ligand efficient inhibitors of multiple kinases, suitable as starting points for further optimization. The binding modes of representative diazaspirocyclic motifs were confirmed by protein crystallography. Selectivity profiles were influenced by the hinge binder group and the interactions of basic nitrogen atoms in the scaffold with acidic side-chains of residues in the ATP pocket. The introduction of more complex substitution to the diazaspirocycles increased potency and varied the selectivity profiles of these initial hits through engagement of the P-loop and changes to the spirocycle conformation, demonstrating the potential of these core scaffolds for future application to kinase inhibitor discovery.

I hope this article can help some friends in scientific research. I am very proud of our efforts over the past few months and hope to 1023595-19-8, help many people in the next few years.Computed Properties of C14H26N2O2

Reference：
Piperidine – Wikipedia,
Piperidine | C5H20915N – PubChem

Chemistry is the experimental and theoretical study of materials on their properties at both the macroscopic and microscopic levels.In a patent£¬ SDS of cas: 1023595-19-8, Which mentioned a new discovery about 1023595-19-8

The present invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof.

I hope this article can help some friends in scientific research. I am very proud of our efforts over the past few months and hope to 1023595-19-8, help many people in the next few years.SDS of cas: 1023595-19-8

Reference£º
Piperidine – Wikipedia,
Piperidine | C5H20925N – PubChem

1023595-19-8, 9-Boc-2,9-diazaspiro[5.5]undecane is a piperidines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

To a solution of (2R,6R)-4-(7-cyanopyrazolo[1,5-a]pyridin-4-yl)-6-methyl-morpholin-2- yl]methyl trifluoromethanesulfonate (compound 67c, 30 mg, 71 mumol), tert-butyl 2,9- diazaspiro[5.5]undecane-9-carboxylate (27 mg, 0.11 mmol) in ACN (4 mL) was added K2CO3 (20 mg, 0.14 mmol). After being stirred at rt for 3 hrs, the reaction mixture was diluted with ACN, and filtered through celite. The filtrate was concentrated to give a yellow solid. The solid was dissolved in DCM (2 mL), and TFA (1 mL) was added dropwise. The reaction mixture was stirred at rt for 1.5 hrs, then concentrated to give a crude product which was purified by prep- HPLC to afford Example 67 (34 mg) as a light yellow powder. MS: calc?d 427 (MH+), measured 427 (MH+).1H NMR (400 MHz, METHANOL-d4) d 8.02 (d, J = 3.5 Hz, 1H), 7.45 (d, J = 7.8 Hz, 1H), 6.56 (d, J = 7.9 Hz, 1H), 4.39 (br t, J = 9.4 Hz, 1H), 4.14 – 3.98 (m, 1H), 3.81 – 3.52 (m, 4H), 3.43 – 3.35 (m, 1H), 3.32 – 3.23 (m, 5H), 3.14 – 2.86 (m, 2H), 2.81 – 2.63 (m, 2H), 2.20 – 1.62 (m, 7H), 1.57 – 1.39 (m, 1H), 1.31 (d, J = 6.2 Hz, 3H).

1023595-19-8, As the paragraph descriping shows that 1023595-19-8 is playing an increasingly important role.

Reference£º
Patent; F. HOFFMANN-LA ROCHE AG; HOFFMANN-LA ROCHE INC.; LIU, Haixia; SHEN, Hong; ZHU, Wei; HU, Taishan; ZHANG, Zhiwei; DEY, Fabian; (91 pag.)WO2020/52738; (2020); A1;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem